Health care utilization & costs for cystic fibrosis patients with pulmonary infections

Managed Care

Volumn 20, Issue 2, 2011, Pages 37-44

  O'Sullivan, Amy K ^a   Sullivan, Jane ^a   Higuchi, Keiko ^a   Montgomery, A Bruce ^b  

^a I3 Innovus ^*  (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; CHILD; CYSTIC FIBROSIS; ECONOMICS; FEMALE; HEALTH SERVICE; HUMAN; INSURANCE; MALE; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT DISEASE; REVIEW; UNITED STATES; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGED; CHILD; CYSTIC FIBROSIS; FEMALE; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT DISEASES; UNITED STATES; YOUNG ADULT;

EID: 79952048716     PISSN: 10623388     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (19)

1. Boyle MP. Adult cystic fibrosis. JAMA 2007;298(15):1787-93.
2. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131(6):809-14.
3. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report to the Center Directors, 2005. Bethesda, MD: The Foundation; 2006.
4. Cystic Fibrosis Trust. About Cystic Fibrosis. 2007. http://www.cftrust.org.uk. Accessed: July 30, 2007.
5. Cystic Fibrosis Trust Antibiotic Group. Antibiotic Treatment for Cystic Fibrosis, 2nd edition. Kent, UK: The Trust; 2002 May.
6. Cystic Fibrosis Worldwide. Annual report 2005. http://wwwcfww.org. Accessed: July 31, 2007.
7. Cystic Fibrosis Worldwide. International support for the 1st European cystic fibrosis awareness day. 2007. http://www.cfww.org/CFE/cfe.awareness-day-international.asp. Accessed: July 31, 2007.
8. Davis PB, Drumm M, Konstan MW. State of the art: Cystic fibrosis. Am J Respir Crit Care Med 1996;154(5):1229-56.
9. European Lung Foundation. 2009. http://www.european-lung-foundation.org. Accessed: April 6, 2009.
10. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007 Nov 15;176(10):957-69.
11. The French National Cystic Fibrosis Observatory (ONM): Report on 2004 Data. 2006. www.vaincrelamuco.org. Accessed: July 31, 2007.
12. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12(3):158-61.
13. 1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007;176(11):1084-1089.
14. Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72.
15. Oster G, Huse DM, Lacey MJ, Regan MM, Fuchs HJ. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Ann Pharmacother 1995;29(5):459-64.
16. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19(1):10-15.
17. Pittman J, Calloway H, Yeatts J, et al. Age of pseudomonas aeruginosa infection and severity of adult lung disease in cystic fibrosis [abstract 332]. Pediatr Pulmonol 2008;43(S31):319.
18. Rosenberg MA, Farrell PM. Assessing the cost of cystic fibrosis diagnosis and treatment. J Pediatr 2005;147(3 Suppl):S101-5.
19. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic Fibrosis Adult Care: Consensus Conference Report. Chest 2004;125:1-39.